Perlmutter Cancer Center

This is a research study involving two study drugs, CX-072 and Ipilimumab (also known as Yervoy). This research study is being done to look at: • The possible side effects, safety and tolerability of CX-072 when given in combination with ipilimumab in participants with solid tumors. • Evidence of anti-cancer activity responses in participants receiving CX-072 in combination with ipilimumab, including whether CX-072 given in combination with ipilimumab causes your type of tumor to shrink, or stops your tumor from getting bigger, and how long participants live. • The amount of CX-072 and ipilimumab in your blood and how long they remain in your body (pharmacokinetics [PK]). • Whether or not your body develops antibodies to CX-072 and ipilimumab that may affect its ability to attach to your tumor (immunogenicity). • Levels of certain markers in your tumor or blood which might help better understand how your cancer reacts to CX-072 in combination with ipilimumab (biomarkers). • Whether or not there are any changes to your tumor mutation burden (a measurement of the number of mutations in the DNA of your tumor) and whether it affects how your tumor reacts to study treatment.